STOCK GOODIES PLAYS OF THE WEEK

[stock1ace1]

GRST Price Traget Issued @ .80 Chart's+DD





Investor Update: Updated March 15, 2013

GRST Upgraded Based on Expansion of Treatement Facilities, Earnings Watch

(NEW YORK)--Ludlow Research, a New York based equity research firm has updated its research opinion on Greenestone Healthcare Corp. (OTC:GRST), a provider of addiction treatment clinic centers in Canada, with a new tentative price target of $0.80 per share.

GRST was upgraded on the heels of their news that they have received endorsement from Ontario Police Department for their treatment of Post Traumatic Stress Disorder (PTSD), and execution of new facility that will focus specifically on this ailment. In addition, GRST is expected to report their financial earnings in the coming weeks, thus Ludlow Research is projecting positive revenue results based on their previous growth rates.

Investor Highlights

- Revenues Increasing Sharply
- Net Loss Decreasing
- On Track to Profitability
- Expanding Addiction Treatment Centers
- Target of $0.80 Issued

Greenestone Healthcare primary business is providing and managing addiction treatment centers in Canada. Currently the company operates 4 clinics, and is expected to increase these operation centers dramatically in the coming months through acquisitions. Since opening their first clinic in 2011, the company has experienced a sharp increase in revenues, and based on their growth looks primed to move into profitability within the coming months of 2013.Current

Financial Earnings

For the nine months ending Set. 30, 2012, the Company reported total revenues increased nearly 300% to $3,941,360, as compared to $1,017,431 for the same time period in 2011. For the same period, total net loss decreased nearly 33% from ($1,051,536), or ($0.07) EPS, for the nine months ending Sept. 30, 2012, compared to a net loss of ($1,767,735), or ($0.33) EPS, for the same period in 2011.

GreeneStone opened its addiction treatment center in the third quarter of 2011, and took its first patients in July and August, most of which were done at nominal or no fee. Clients began to increase in September at a steady pace and the company generated $213,035 in revenue from the treatment center during the third quarter of 2011. Revenue in the third quarter of 2012 grew to $884,036, a 315% increase over the same period the previous year, with revenue in the third quarter was only slightly better than the revenue in the second quarter. Revenue in the third quarter was impacted by a very slow period in the middle of the summer, and the company has learned that this is a traditionally slow period in the addiction treatment business and will be better prepared in the coming year for this type of slowdown.

The Company is seeking to significantly increase its capacity at its in-patient treatment facility from 36 beds to 300 beds over the next twenty four months.

Share Structure

As of Feb. 18, 2013, the Company has around 24 million shares issued and outstanding, of which around 16.5 million was held by insiders and restricted from resale, and a public float of around 7.5million shares.

Valuation Target

Based on their revenue growth rate, plans to expand bed capacity to 200 beds, launch of treatment facility for PTSD, and tight public float and technical indicators on chart, Ludlow Research has upgraded their valuation target on GRST to $0.80 per share.

Investor Mailing List and Feedback Form

If you would like to be added to GRST investor mailing list to receive updates on news, upcoming events, research notes, or to submit a question to the company, please register online at http://www.wallstreetnewscast.com/request/grst.html